Why the study?
Does rosuvastatin 10 mg daily reduce NT-proBNP levels in HIV-infected patients on stable antiretroviral therapy without overt heart failure?
RCT (n=147)
Does rosuvastatin 10 mg daily reduce NT-proBNP levels in HIV-infected patients on stable antiretroviral therapy without overt heart failure?
Rosuvastatin 10 mg daily significantly reduces plasma NT-proBNP levels over 96 weeks in HIV-infected patients on stable antiretroviral therapy without overt heart failure.
Answers are grounded in this paper and cite their sources.
Supports statin consideration to mitigate cardiac risk in HIV; extends evidence to biomarker endpoints in antiretroviral-treated patients.
OBJECTIVE: HIV-infected participants are at a higher risk for cardiovascular disease (CVD). N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a significant predictor of CVD in the general population and is associated with mortality in HIV. DESIGN AND METHODS: The 96-week Stopping Atherosclerosis and Treating Unhealthy Bone with Rosuvastatin in HIV (SATURN-HIV) trial randomized 147 patients on stable antiretroviral therapy with low-density lipoprotein-cholesterol level lower than 130 mg/dl and without overt heart failure to 10 mg daily rosuvastatin or placebo. We measured NT-proBNP levels by enzyme-linked immunosorbent assay (ELISA). Baseline and changes in NT-proBNP were compared between groups. Spearman correlation was used to explore relationships between baseline NT-proBNP, inflammation, and CVD risk markers. Multivariable analyses were conducted to assess associations with NT-proBNP levels. RESULTS: Median age was 46 years, 80% were men, 69% were African American, and 46% were on protease inhibitors. At baseline, median (Q1, Q3) NT-proBNP was higher in the rosuvastatin group than placebo [41 (20, 66.5) versus 25 pg/ml (11, 56), P = 0.012)]. Baseline NT-proBNP correlated with bulb and common carotid artery intima-media thickness, coronary calcium score, interleukin 6, and cystatin C. After 96 weeks, median NT-proBNP decreased significantly in the rosuvastatin group versus placebo (-1.50 versus +4.50 pg/ml, P = 0.041). Within the rosuvastatin group, changes in NT-proBNP were negatively correlated with changes in insulin resistance and total limb fat. CONCLUSION: Rosuvastatin reduces plasma NT-proBNP in HIV-infected participants on antiretroviral therapy. NT-proBNP correlated with several measures of CVD risk, independent of inflammation markers.
No takes yet. Share an insight, caveat, or question.
Dirajlal‐Fargo et al. (2014) conducted an RCT in HIV (n=147). rosuvastatin vs. placebo was evaluated on change in NT-proBNP levels (p=0.041).
Synapse has enriched 10 related papers. Consider them for comparative context: